Cargando…
Antibody cocktail effective against variants of SARS-CoV-2
BACKGROUND: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus with a high mutation rate. Importantly, several currently circulating SARS-CoV-2 variants are associated with loss of efficacy for both vaccines and neutralizing an...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609252/ https://www.ncbi.nlm.nih.gov/pubmed/34814920 http://dx.doi.org/10.1186/s12929-021-00777-9 |
_version_ | 1784602890949623808 |
---|---|
author | Liang, Kang-Hao Chiang, Pao-Yin Ko, Shih-Han Chou, Yu-Chi Lu, Ruei-Min Lin, Hsiu-Ting Chen, Wan-Yu Lin, Yi-Ling Tao, Mi-Hua Jan, Jia-Tsrong Wu, Han-Chung |
author_facet | Liang, Kang-Hao Chiang, Pao-Yin Ko, Shih-Han Chou, Yu-Chi Lu, Ruei-Min Lin, Hsiu-Ting Chen, Wan-Yu Lin, Yi-Ling Tao, Mi-Hua Jan, Jia-Tsrong Wu, Han-Chung |
author_sort | Liang, Kang-Hao |
collection | PubMed |
description | BACKGROUND: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus with a high mutation rate. Importantly, several currently circulating SARS-CoV-2 variants are associated with loss of efficacy for both vaccines and neutralizing antibodies. METHODS: We analyzed the binding activity of six highly potent antibodies to the spike proteins of SARS-CoV-2 variants, assessed their neutralizing abilities with pseudovirus and authentic SARS-CoV-2 variants and evaluate efficacy of antibody cocktail in Delta SARS-CoV-2-infected hamster models as prophylactic and post-infection treatments. RESULTS: The tested RBD-chAbs, except RBD-chAb-25, maintained binding ability to spike proteins from SARS-CoV-2 variants. However, only RBD-chAb-45 and -51 retained neutralizing activities; RBD-chAb-1, -15, -25 and -28 exhibited diminished neutralization for all SARS-CoV-2 variants. Notably, several cocktails of our antibodies showed low IC(50) values (3.35–27.06 ng/ml) against the SARS-CoV-2 variant pseudoviruses including United Kingdom variant B.1.1.7 (Alpha), South Africa variant B.1.351 (Beta), Brazil variant P1 (Gamma), California variant B.1.429 (Epsilon), New York variant B.1.526 (Iota), and India variants, B.1.617.1 (Kappa) and B.1.617.2 (Delta). RBD-chAb-45, and -51 showed PRNT(50) values 4.93–37.54 ng/ml when used as single treatments or in combination with RBD-chAb-15 or -28, according to plaque assays with authentic Alpha, Gamma and Delta SARS-CoV-2 variants. Furthermore, the antibody cocktail of RBD-chAb-15 and -45 exhibited potent prophylactic and therapeutic effects in Delta SARS-CoV-2 variant-infected hamsters. CONCLUSIONS: The cocktail of RBD-chAbs exhibited potent neutralizing activities against SARS-CoV-2 variants. These antibody cocktails are highly promising candidate tools for controlling new SARS-CoV-2 variants, including Delta. |
format | Online Article Text |
id | pubmed-8609252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86092522021-11-23 Antibody cocktail effective against variants of SARS-CoV-2 Liang, Kang-Hao Chiang, Pao-Yin Ko, Shih-Han Chou, Yu-Chi Lu, Ruei-Min Lin, Hsiu-Ting Chen, Wan-Yu Lin, Yi-Ling Tao, Mi-Hua Jan, Jia-Tsrong Wu, Han-Chung J Biomed Sci Research BACKGROUND: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus with a high mutation rate. Importantly, several currently circulating SARS-CoV-2 variants are associated with loss of efficacy for both vaccines and neutralizing antibodies. METHODS: We analyzed the binding activity of six highly potent antibodies to the spike proteins of SARS-CoV-2 variants, assessed their neutralizing abilities with pseudovirus and authentic SARS-CoV-2 variants and evaluate efficacy of antibody cocktail in Delta SARS-CoV-2-infected hamster models as prophylactic and post-infection treatments. RESULTS: The tested RBD-chAbs, except RBD-chAb-25, maintained binding ability to spike proteins from SARS-CoV-2 variants. However, only RBD-chAb-45 and -51 retained neutralizing activities; RBD-chAb-1, -15, -25 and -28 exhibited diminished neutralization for all SARS-CoV-2 variants. Notably, several cocktails of our antibodies showed low IC(50) values (3.35–27.06 ng/ml) against the SARS-CoV-2 variant pseudoviruses including United Kingdom variant B.1.1.7 (Alpha), South Africa variant B.1.351 (Beta), Brazil variant P1 (Gamma), California variant B.1.429 (Epsilon), New York variant B.1.526 (Iota), and India variants, B.1.617.1 (Kappa) and B.1.617.2 (Delta). RBD-chAb-45, and -51 showed PRNT(50) values 4.93–37.54 ng/ml when used as single treatments or in combination with RBD-chAb-15 or -28, according to plaque assays with authentic Alpha, Gamma and Delta SARS-CoV-2 variants. Furthermore, the antibody cocktail of RBD-chAb-15 and -45 exhibited potent prophylactic and therapeutic effects in Delta SARS-CoV-2 variant-infected hamsters. CONCLUSIONS: The cocktail of RBD-chAbs exhibited potent neutralizing activities against SARS-CoV-2 variants. These antibody cocktails are highly promising candidate tools for controlling new SARS-CoV-2 variants, including Delta. BioMed Central 2021-11-23 /pmc/articles/PMC8609252/ /pubmed/34814920 http://dx.doi.org/10.1186/s12929-021-00777-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Liang, Kang-Hao Chiang, Pao-Yin Ko, Shih-Han Chou, Yu-Chi Lu, Ruei-Min Lin, Hsiu-Ting Chen, Wan-Yu Lin, Yi-Ling Tao, Mi-Hua Jan, Jia-Tsrong Wu, Han-Chung Antibody cocktail effective against variants of SARS-CoV-2 |
title | Antibody cocktail effective against variants of SARS-CoV-2 |
title_full | Antibody cocktail effective against variants of SARS-CoV-2 |
title_fullStr | Antibody cocktail effective against variants of SARS-CoV-2 |
title_full_unstemmed | Antibody cocktail effective against variants of SARS-CoV-2 |
title_short | Antibody cocktail effective against variants of SARS-CoV-2 |
title_sort | antibody cocktail effective against variants of sars-cov-2 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609252/ https://www.ncbi.nlm.nih.gov/pubmed/34814920 http://dx.doi.org/10.1186/s12929-021-00777-9 |
work_keys_str_mv | AT liangkanghao antibodycocktaileffectiveagainstvariantsofsarscov2 AT chiangpaoyin antibodycocktaileffectiveagainstvariantsofsarscov2 AT koshihhan antibodycocktaileffectiveagainstvariantsofsarscov2 AT chouyuchi antibodycocktaileffectiveagainstvariantsofsarscov2 AT lurueimin antibodycocktaileffectiveagainstvariantsofsarscov2 AT linhsiuting antibodycocktaileffectiveagainstvariantsofsarscov2 AT chenwanyu antibodycocktaileffectiveagainstvariantsofsarscov2 AT linyiling antibodycocktaileffectiveagainstvariantsofsarscov2 AT taomihua antibodycocktaileffectiveagainstvariantsofsarscov2 AT janjiatsrong antibodycocktaileffectiveagainstvariantsofsarscov2 AT wuhanchung antibodycocktaileffectiveagainstvariantsofsarscov2 |